Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 794.18 USD -0.26%
Market Cap: 753.9B USD
Have any thoughts about
Eli Lilly and Co?
Write Note

Operating Margin
Eli Lilly and Co

35.3%
Current
30%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
35.3%
=
Operating Profit
14.4B
/
Revenue
40.9B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Eli Lilly and Co
NYSE:LLY
749.1B USD
35%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
348B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.1B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
150.1B USD
22%
IE
Endo International PLC
LSE:0Y5F
147.1B USD
11%
Country US
Market Cap 749.1B USD
Operating Margin
35%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 348B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 150.1B USD
Operating Margin
22%
Country IE
Market Cap 147.1B USD
Operating Margin
11%
No Stocks Found

Eli Lilly and Co
Glance View

Market Cap
754.4B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.

LLY Intrinsic Value
334.42 USD
Overvaluation 58%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
35.3%
=
Operating Profit
14.4B
/
Revenue
40.9B
What is the Operating Margin of Eli Lilly and Co?

Based on Eli Lilly and Co's most recent financial statements, the company has Operating Margin of 35.3%.